Intellia Therapeutics Inc

Research Intellia Therapeutics Inc (NTLA) on Bullrun: market cap USD 2.32B. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerNTLA
• ExchangeNASDAQ
• CountryUnited States
• SectorHealthcare
• IndustryBiotechnology
• CurrencyUSD
• Market capUSD 2.32B
• Financial periodFY2025
• RevenueUSD 67.67M
• Revenue growth16.9%
• Net income-USD 412.69M
• Free cash flow-USD 395.87M

Valuation Snapshot

latest market cap is USD 2.32B.

About Intellia Therapeutics Inc

Intellia Therapeutics, Inc. operates as a clinical-stage genome editing company focused on developing potentially curative therapeutics using CRISPR/Cas9-based technologies. The company offers clustered, regularly interspaced short palindromic repeats (“CRISPR”)/CRISPR associated 9 (“Cas9”) technology for genome editing. The company provides a modular platform, to advance in vivo and ex vivo therapies for diseases.

Frequently asked questions

What is Intellia Therapeutics Inc's market cap?

Intellia Therapeutics Inc's market capitalization is USD 2.32B.

What does Intellia Therapeutics Inc do?

Intellia Therapeutics, Inc. operates as a clinical-stage genome editing company focused on developing potentially curative therapeutics using CRISPR/Cas9-based technologies.